Abbott Laboratories (NYSE: ABT – Get Rating) ‘s share price reached a new 52-week low during mid-day trading on Tuesday. The stock traded as low as $ 103.31 and last traded at $ 103.61, with a volume of 44085 shares. The stock had previously closed at $ 105.91.
Several research analysts have issued reports on ABT shares. Wells Fargo & Company decreased their price target on shares of Abbott Laboratories from $ 155.00 to $ 150.00 and set an “overweight” rating on the stock in a research report on Friday, April 8th. Royal Bank of Canada decreased their price objective on shares of Abbott Laboratories from $ 146.00 to $ 143.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Bank of America began coverage on shares of Abbott Laboratories in a research note on Tuesday, March 1st. They issued a “buy” rating and a $ 140.00 price objective for the company. StockNews.com began coverage on shares of Abbott Laboratories in a research note on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, Raymond James decreased their price objective on shares of Abbott Laboratories from $ 143.00 to $ 135.00 and set an “outperform” rating for the company in a research note on Thursday, April 21st. Two equities research analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $ 140.25.
The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.40 and a current ratio of 1.85. The firm’s 50 day moving average is $ 114.69 and its 200-day moving average is $ 122.49. The firm has a market cap of $ 183.50 billion, a price-to-earnings ratio of 24.32, a price-to-earnings-growth ratio of 3.93 and a beta of 0.73.
Abbott Laboratories (NYSE: ABT – Get Rating) last announced its earnings results on Wednesday, April 20th. The healthcare product maker reported $ 1.73 EPS for the quarter, topping the consensus estimate of $ 1.47 by $ 0.26. The firm had revenue of $ 11.90 billion for the quarter, compared to the consensus estimate of $ 11 billion. Abbott Laboratories had a net margin of 17.35% and a return on equity of 28.72%. The business’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter last year, the firm posted $ 1.32 EPS. As a group, research analysts predict that Abbott Laboratories will post 4.85 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Investors of record on Friday, July 15th will be issued a $ 0.47 dividend. The ex-dividend date of this dividend is Thursday, July 14th. This represents a $ 1.88 annualized dividend and a yield of 1.79%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 43.62%.
In other news, Director Daniel J. Starks sold 50,000 shares of Abbott Laboratories stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $ 113.22, for a total transaction of $ 5,661,000.00. Following the sale, the director now directly owns 6,973,500 shares in the company, valued at approximately $ 789,539,670. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Randel William Woodgrift sold 24,000 shares of Abbott Laboratories stock in a transaction dated Wednesday, May 4th. The shares were sold at an average price of $ 113.00, for a total transaction of $ 2,712,000.00. Following the sale, the senior vice president now owns 47,854 shares in the company, valued at $ 5,407,502. The disclosure for this sale can be found here. Insiders own 0.52% of the company stock.
Large investors have recently added to or reduced their stakes in the business. KB Financial Partners LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $ 27,000. Blue Bell Private Wealth Management LLC acquired a new position in Abbott Laboratories in the fourth quarter valued at about $ 30,000. Delos Wealth Advisors LLC boosted its position in Abbott Laboratories by 100.9% in the fourth quarter. Delos Wealth Advisors LLC now owns 231 shares of the healthcare product maker’s stock valued at $ 33,000 after buying an additional 116 shares in the last quarter. Retirement Group LLC lifted its position in shares of Abbott Laboratories by 1,125.0% during the fourth quarter. Retirement Group LLC now owns 245 shares of the healthcare product maker’s stock worth $ 34,000 after purchasing an additional 225 shares in the last quarter. Finally, Bourgeon Capital Management LLC acquired a new position in shares of Abbott Laboratories during the first quarter worth approximately $ 30,000. Hedge funds and other institutional investors own 73.46% of the company stock.
About Abbott Laboratories: (NYSE: ABT)
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Receive News & Ratings for Abbott Laboratories Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Abbott Laboratories and related companies with MarketBeat.com’s FREE daily email newsletter.